Monthly Archives: August 2019
An Unfortunate Consequence of Duodenogastric Reflux
Kurt J. Isselbacher, M.D., 1925-2019
Efficacy of Glecaprevir and Pibrentasvir in Patients with Genotype 1 Hepatitis C Virus Infection with Treatment Failure after NS5A Inhibitor Plus Sofosbuvir Therapy
Treatment options are limited for patients with hepatitis C (HCV) infection with treatment failure after sofosbuvir plus an NS5A inhibitor. There are some data for the efficacy of glecaprevir/pibrentasvir (G/P) in these patients. We performed a randomi… Continue reading
Infliximab–Tumor Necrosis Factor Complexes Elicit Formation of Anti-drug Antibodies
Some patients develop anti-drug antibodies (ADAs), which reduce the efficacy of infliximab, a monoclonal antibody against tumor necrosis factor (TNF), in treatment of immune-mediated diseases, including inflammatory bowel diseases. ADAs arise inconsist… Continue reading
How to Advance Research, Education and Training in the Study of Rare Diseases
Inflammation-induced Occludin Downregulation Limits Epithelial Apoptosis by Suppressing Caspase 3 Expression
Epithelial tight junctions are compromised in patients with gastrointestinal disease. Occludin is a protein component of tight junctions; its removal from tight junctions or reduced expression results in barrier loss. Knockout (KO) of occludin in mice,… Continue reading